Novo Nordisk shares declined nearly 3% pre-market, extending losses from Monday's CagriSema failure. However, the company reported positive Phase 2 data from China, showing its obesity drug UBT251 achieved 19.7% weight loss. Despite this success, the stock fell, while retail sentiment remained bullish with high message volume.